Aurora Investment Counsel Invests $1.22 Million in Haemonetics Corporation $HAE

Aurora Investment Counsel purchased a new position in Haemonetics Corporation (NYSE:HAE) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 21,595 shares of the medical instruments supplier’s stock, valued at approximately $1,217,000.

Other institutional investors have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Haemonetics by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after buying an additional 971 shares during the last quarter. Caxton Associates LLP bought a new position in shares of Haemonetics during the first quarter worth about $216,000. United Services Automobile Association bought a new position in shares of Haemonetics during the first quarter worth about $212,000. Empowered Funds LLC grew its stake in Haemonetics by 9.1% in the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after purchasing an additional 372 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Haemonetics by 6.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after purchasing an additional 9,051 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Bank of America upgraded Haemonetics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. Weiss Ratings upgraded Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, June 25th. BTIG Research reiterated a “buy” rating and issued a $84.00 price target on shares of Haemonetics in a report on Friday, June 26th. Robert W. Baird set a $67.00 price target on Haemonetics in a report on Friday, May 8th. Finally, Barrington Research dropped their price target on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and an average target price of $78.89.

Haemonetics Price Performance

Shares of NYSE:HAE opened at $77.97 on Friday. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $87.32. The firm has a 50-day simple moving average of $70.49 and a 200 day simple moving average of $66.25. The company has a market cap of $3.54 billion, a PE ratio of 38.60, a P/E/G ratio of 1.57 and a beta of 0.52.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm had revenue of $346.35 million for the quarter, compared to analysts’ expectations of $336.83 million. During the same quarter last year, the company posted $1.24 earnings per share. Haemonetics’s revenue was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, sell-side analysts anticipate that Haemonetics Corporation will post 5.21 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.